ESR1 and triple-negative breast carcinoma: Despite these advances, there are currently no targeted therapies for triple negative breast cancers (TNBC) available, which are characterized only by the absence of estrogen receptor (ER), progesterone receptor (PR) and lack of amplification of the HER2/neu oncogene5.